Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Buys 3,959 Shares

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt purchased 3,959 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was bought at an average price of $3.30 per share, with a total value of $13,064.70. Following the acquisition, the insider directly owned 82,556 shares in the company, valued at approximately $272,434.80. This represents a 5.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of SHPH opened at $3.65 on Friday. Shuttle Pharmaceuticals Holdings, Inc. has a 1 year low of $2.90 and a 1 year high of $55.90. The company’s 50 day simple moving average is $5.80 and its 200 day simple moving average is $10.64. The company has a market capitalization of $2.34 million, a price-to-earnings ratio of -0.08 and a beta of 0.29.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share for the quarter.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Ikarian Capital LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter worth about $124,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter valued at approximately $37,000. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals during the fourth quarter worth approximately $26,000. Finally, Connective Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals in the third quarter worth $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .